Why so much excitement about CAR-T cells?

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 18 July 2017 In News, Science, Treatment

July 12, 2017, marked a historic day for medicine and for the US Food and Drug Administration (FDA) when an expert advisory committee to the FDA unanimously endorsed the first ever genetically engineered, cell-based therapy for use in patients.

Read More


Melanoma Treatments: Breakthroughs for Multiple Cancers — for Real and Right Now

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 10 July 2017 In Science, Treatment

While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?

Read More


Sunscreen Laws may Hinder Protecting Children from Exposure

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In News, Policy, Prevention

With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure. Yet, something remaining a central concern among those parents is the public policy surrounding use of sunscreen in schools.

Read More


Melanoma Research Alliance and the American Cancer Society Forge Research Partnership to Maximize Immunotherapy Benefit to Patients

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In Allies & Partnerships, Science

The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing rare, but serious, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.

Read More


MAC: A Valued Partner in the Fight Against Melanoma

By Michael Kaplan, MRA President & CEO | 10 July 2017 In Allies & Partnerships

What do you do after the melanoma diagnosis has settled in and you’ve done all you can to ensure the best health outcome for yourself? Or even worse, what do you do after you’ve lost a spouse or a child to melanoma? For the members of the Melanoma Action Coalition, the answer is clear. You take that fear or sorrow, and you mobilize.

Read More


Non-invasive Detection Modalities and Metastatic Risk Stratification for Melanoma: Where Are We Now?

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 10 July 2017 In Prevention, Science, Treatment

While dermatologists have advocated for patient education about irregular skin lesions in order to catch melanomas earlier, dermatologists ultimately play the largest role in the detection and excision of abnormal skin lesions via skin biopsy. However, visual recognition and assessment of pigmented skin lesions is limited to the eye of the dermatologist, and can be challenging for even the most experienced clinicians.

Read More


Melanoma Research Alliance Welcomes New Chief Development Officer

By Pamela Goldsmith, MRA Director of Communications | 10 July 2017 In News

Following 22 years of fundraising and management experience in healthcare, higher education and NPOs, Joan Russo is joining the Melanoma Research Alliance (MRA) as Chief Development Officer.

Read More


Strides and Obstacles in Melanoma Research Spotlight on Martin McMahon, PhD

By Pamela Goldsmith, MRA Director of Communications | 6 June 2017 In Science, Treatment

Like so many in the melanoma research field, Martin McMahon, PhD, Huntsman Cancer Institute’s senior director of pre-clinical translation and Professor at the University of Utah, entered the melanoma field by accident.

Read More


Invincible, Until You’re Not

By Pamela Goldsmith, MRA Director of Communications | 6 June 2017 In Melanoma Stories, Prevention, Treatment

Self described, lifetime sun worshiper and tanning bed devotee, 24-year old native Texan Ali Young was barely daunted the first time she was diagnosed with deadly skin cancer at the age of 18. Matter of fact, she recalls heading to the tanning bed the very day after her biopsy.

Read More


Melanoma Clinical Oncology Research: Interview with Dr. Joshua Arbesman

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 6 June 2017 In Science, Treatment

As a third year medical student, MD Candidate Pooja Rambhia had the privilege of conducting an elective research year under Dr. Joshua Arbesman’s mentorship at University Hospitals Cleveland Medical Center. Arbesman has a unique role in translational basic science research within the realm of familial melanoma.

Read More


Login

×